Welcome to our dedicated page for ROCKWELL MEDICAL SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKWELL MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKWELL MEDICAL's regulatory disclosures and financial reporting.
Rockwell Medical, Inc. reported that it has received notice from Nasdaq that the company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The shares maintained a closing bid of at least $1.00 from July 1, 2026 through July 15, 2026, and Nasdaq has closed the compliance matter. The company states it is now in full compliance with all Nasdaq continued listing requirements, and its common stock remains listed and traded under the ticker RMTI.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide, focused on supporting patients with end-stage kidney disease.
Dawson Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director Joseph H. Dawson received an equity grant and his holdings were adjusted for a reverse split. On July 1, 2026, he was granted 9,633 shares in the form of restricted stock units at no cash cost. These units vest on July 1, 2027, if he continues serving through the 2027 annual meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical completed a 1-for-10 reverse split of its common stock, and his existing shareholdings and equity awards were proportionately reduced. After giving effect to both the grant and the reverse split adjustments, Dawson beneficially owns 12,133 shares of common stock directly.
Nissenson Allen reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Allen Nissenson received a grant of 9,633 shares of Common Stock as a compensation award, recorded at a price of $0.0000 per share. These shares are in the form of restricted stock units that vest on July 1, 2027, subject to his continued service through the 2027 annual meeting.
The company also completed a 1-for-10 reverse split of its common stock effective 12:01 a.m. on July 1, 2026, which reduced the number of shares held and adjusted outstanding equity awards. After these changes and the grant, Nissenson beneficially owns 23,892 shares directly.
Lau Joan reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Joan Lau received a grant of 9,633 shares of Common Stock as a stock award, with no cash paid per share. These restricted stock units vest on July 1, 2027, subject to her continued service through the 2027 Annual Meeting. A 1-for-10 reverse split effective July 1, 2026 adjusted her holdings to 20,944 shares after the reported grant.
Radie Robert S reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Robert S. Radie received an award of 9,633 shares of common stock as a grant of restricted stock units, with no cash paid per share. Following this grant, he beneficially owns 23,985 shares directly.
The restricted stock units vest on July 1, 2027, subject to his continued service through the company’s 2027 annual meeting. The company also implemented a 1-for-10 reverse stock split effective July 1, 2026, and Radie’s reported shareholdings and equity awards have been adjusted to reflect this split.
COOPER JOHN G reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director John G. Cooper received an equity award rather than buying shares on the market. On July 1, 2026, he was granted 9,633 restricted stock units of common stock at no cash cost as compensation.
The RSUs vest on July 1, 2027, subject to his continued service through the 2027 Annual Meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical implemented a 1-for-10 reverse stock split, and Cooper’s equity awards and holdings were proportionally adjusted. Following these adjustments and the reported grant, he beneficially owns 23,670 shares of common stock directly.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. granted SVP and CCO Timothy Chole 15,000 shares of Common Stock as a compensation award, recorded at $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on his continued service.
The company effected a 1-for-10 reverse split of its common stock effective at 12:01 AM on July 1, 2026. Following the grant and split adjustment, Chole beneficially owns 27,285 shares of Rockwell Medical common stock directly.
Hunter Heather reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical Chief Operating Officer Heather Hunter reported receiving an award of 15,000 shares of common stock as compensation, at a stated price of $0.00 per share. Following this grant, she directly holds 28,007 shares of the company’s stock.
Footnotes explain that these are restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, as long as she continues serving the company. The company also effected a 1-for-10 reverse stock split effective just after midnight on July 1, 2026, and her reported post-transaction holdings reflect this adjustment to both shares and outstanding equity awards.
TIMMINS MEGAN C. reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. executive Megan C. Timmins, EVP, CLO & Secretary, received a grant of 15,000 shares of common stock as restricted stock units at no cash cost. These RSUs vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on her continued service.
The filing also notes a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced her share count and adjusted outstanding equity awards. Following the grant and split adjustment, she beneficially owns 31,240 shares of common stock directly.
Neri Jesse reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. SVP and CFO Jesse Neri received a grant of 15,000 shares of common stock as a stock award, rather than an open-market purchase, at a stated price of $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service to the company.
Effective at 12:01 AM on July 1, 2026, the company completed a 1-for-10 reverse split of its common stock and adjusted outstanding equity awards. After reflecting both the reverse split and this award, Neri directly holds 27,239 shares of Rockwell Medical common stock.